GlassScriptPhysician profile
Paul Crossan
NPI 1669465936
$957.08
in general payments reported to CMS, 2019-2025
22 companies · $71.18 in 2025
The $71.18 reported for 2025 was less than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $309 · 2020: $184 · 2021: $144 · 2022: $79.08 · 2023: $101 · 2024: $69.17 · 2025: $71.18.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $241.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $241.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Isoray, INC | $199.94 | 2020-2023 | Brachytherapy Source |
| Astrazeneca Pharmaceuticals LP | $126.64 | 2020-2025 | Lynparza |
| Genzyme Corporation | $123.25 | 2019 | |
| Gt Medical Technologies, INC | $60.55 | 2023-2024 | Gammatile, Gammatile |
| Bayer Healthcare Pharmaceuticals INC. | $53.34 | 2019-2023 | |
| Amgen INC. | $48.76 | 2019-2020 | |
| Brainlab, INC. | $46.02 | 2024 | Surgical Planning and Navigation Radiation Treatment Planning and Positioning |
| Tactile Systems Technology INC | $32.21 | 2019 | |
| Advanced Accelerator Applications | $31.54 | 2019-2020 | |
| Pharmacyclics LLC, An Abbvie Company | $31.43 | 2020 | |
| Ipsen Biopharmaceuticals, INC | $24.16 | 2019 | |
| Alnylam Pharmaceuticals INC. | $22.89 | 2021 | |
| Dova Pharmaceuticals | $22.20 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $21.45 | 2021 | |
| Merck Sharp & Dohme LLC | $20.65 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rigel Pharmaceuticals, INC. | $19.95 | 2019 | |
| Abbvie INC. | $16.15 | 2019 | |
| Medtronic USA, INC. | $13.17 | 2019 | |
| Sysmex Inostics INC | $12.29 | 2019 | |
| Jazz Pharmaceuticals INC. | $11.65 | 2020 | |
| Aurobindo Pharma USA, INC. | $11.30 | 2020 | |
| Fortovia Therapeutics, INC. | $7.54 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Crossan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.